# Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.

> **NCT07162467** · — · ENROLLING_BY_INVITATION · sponsor: **Tianjin Anding Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07162467
- **Lead sponsor:** Tianjin Anding Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-02-19
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07162467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07162467, "Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07162467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*